Aptose Biosciences Inc.

APTONASDAQHealthcare

$1.71

+$1.71(+100.00%)

Market Cap$4364655

P/E Ratio—

52W High$43.191

52W Low$1.1

Avg Volume223K

Open$1.71

Beta1.13

Overview

Aptose Biosciences Inc. (APTO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

APTO · free cash flow · updated Jun 9, 2026

Core FCF metrics

APTO · FCF · TTM · margin & CAGR

Free cash flow was $0 for FY2025 (fiscal year ending 2025-12-31), up 100.0% year-over-year

FY2025 Free Cash Flow$0▲ +100.0% YoY

Trailing 12M (TTM)$0trailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

APTO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$0(0M)$0▲ +100.0%—

FY2024−$36.0M(0M)−$36.0M▲ +19.4%—

FY2023−$44.6M(0M)−$44.6M▼ 37.9%—

FY2022−$32.3M(0M)−$32.3M▲ +25.7%—

FY2021−$43.3M(0M)−$43.5M▼ 28.1%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

APTO · P/FCF · FCF yield · FCF per share

Aptose Biosciences Inc. (APTO) reported negative free cash flow of —. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

APTO · cash flow statement · operating / investing / financing

For FY2025, Aptose Biosciences Inc. generated $0 in operating cash flow and spent 0M in capital expenditures, yielding $0 in free cash flow.

Operating Activities

+$0.0M

Cash from core business operations

2025-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$19.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($0) − |CapEx| (0M) = FCF ($0)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

APTO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Aptose Biosciences Inc.YOU

APTO

$0+100.0%—

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Aptose Biosciences Inc. (APTO) reported free cash flow of $0 for FY2025 (fiscal year ending 2025-12-31), up 100.0% year-over-year.

Aptose Biosciences Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

APTO free cash flow · 8 questions

Aptose Biosciences Inc. free cash flow was $0 for FY2025, up 100.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $0.

APTO free cash flowAPTO FCFAPTO FCF 2025APTO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Aptose Biosciences Inc. · Aptose Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026